<DOC>
	<DOCNO>NCT02354391</DOCNO>
	<brief_summary>The objective study determine efficacy , safety , patient satisfaction pretreatment Picato® gel 4 day prior methyl aminolevulinate photodynamic therapy ( MAL PDT ) . Patients diagnose actinic keratosis eligible receive topical treatment ingenol mebutate ( Picato® ) photodynamic therapy act test group control group . Each patient four distinct treatment area 25cm2 scalp , and/or scalp face . Three treatment area receive Picato® 0.015 % gel , MAL PDT , Picato® 0.015 % MAL PDT combine . One area serve control receive none treatment .</brief_summary>
	<brief_title>Ingenol Mebutate ( Picato® ) With Methyl Aminolevulinate Photodynamic Therapy Treatment Actinic Keratosis</brief_title>
	<detailed_description>Study Objective The objective study determine efficacy , safety patient satisfaction pretreatment Picato® gel 4 day prior methyl aminolevulinate photodynamic therapy ( MAL PDT ) . This test area compare Picato® treatment alone MAL PDT alone treatment area well control field ( treatment ) . Rationale This study focus topical treatment actinic keratosis . Patients diagnose actinic keratosis eligible receive topical treatment ingenol mebutate ( Picato® ) photodynamic therapy act test group control group . Patients follow appointment study nurse dermatologist . Patient treatment eligibility regimen prescribe medication Dr. Rivers ( patient 's ) discretion . Patients follow study duration one complete treatment plus 2 month . Study duration : The inclusion period 6 month , depend speed patient recruitment . The study duration individual patient end eight week treatment completion .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<mesh_term>Methyl 5-aminolevulinate</mesh_term>
	<criteria>1 . Age &gt; 40 yr 2 . Patients eligible receive topical treatment ingenol mebutate gel photodynamic therapy treatment actinic keratosis discretion dermatologist . 3 . Fitzpatrick Skin Type I &amp; II . 4 . Patient must give informed consent . 1 . Diagnosis Basal Cell Carcinoma ( BCC ) , Squamous Cell Carcinoma ( SCC ) melanoma treatment area . 2 . Currently experience adverse reaction and/or Local Skin Reactions previous Actinic Keratosis ( AK ) treatment treatment field . 3 . Females pregnant , nurse plan pregnancy participation study . 4 . Female subject childbearing potential ( include subject use surgical sterilization , ie , bilateral tubal ligation implant device method contraception ) positive urine pregnancy test Day 1 prior study treatment ; female consider NOT childbearing potential postmenopausal least 12 consecutive month amenorrhea , undergone bilateral oophorectomy , uterus .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>